使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, ladies and gentlemen, and welcome to Baxter International fourth-quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this call is being recorded by Baxter and its copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.
各位女士、先生,早安,歡迎參加百特國際(Baxter International)2024 年第四季財報電話會議。(接線員指示)提醒各位,本通話由百特錄音,且其內容受著作權保護。未經百特許可,不得錄音或轉播。如有任何異議,請此刻中斷連線。
I would now like to turn the call over to Ms. Clare Trachtman, Senior Vice President, Chief Investor Relations Officer at Baxter International. Ms. Trachtman, you may begin.
現在我想把電話交給百特國際資深副總裁兼投資人關係長 Clare Trachtman 女士。Trachtman 女士,請開始。
Clare Trachtman - Senior Vice President, Chief Investor Relations Officer
Clare Trachtman - Senior Vice President, Chief Investor Relations Officer
Good morning and welcome to our fourth-quarter 2024 earnings conference call. Joining me today are Brent Shafer, Baxter's Chair and Interim Chief Executive Officer; Joel Grade, Baxter's Executive Vice President and Chief Financial Officer; and Heather Knight, Baxter's newly appointed Chief Operating Officer.
早安,歡迎參加我們 2024 年第四季財報電話會議。今天與我一同出席的有:百特董事長兼臨時執行長 Brent Shafer;百特執行副總裁兼財務長 Joel Grade;以及百特新任營運長 Heather Knight。
On the call this morning, we will be discussing Baxter's fourth-quarter and full-year 2024 results, along with our financial outlook for the first-quarter and full-year 2025. With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook for the first quarter and full-year 2025, the anticipated impact of our strategic action, the potential impact of the various regulatory and operational matters in the macroeconomic environment on a result of operations contains forward-looking statements that involve risk and uncertainties. And, of course, our actual results could differ materially from our current expectations.
今天上午的電話會議中,我們將討論百特 2024 年第四季與全年業績,以及我們對 2025 年第一季與全年之財務展望。在此,我先以提醒各位開始我們的事先準備發言:本簡報(包括關於我們 2025 年第一季與全年財務展望、我們策略行動的預期影響,以及宏觀經濟環境中各項監管與營運事項對營運結果之潛在影響的評論)包含前瞻性陳述,涉及風險與不確定性。當然,我們的實際結果可能與目前預期有重大差異。
Please refer to today's press release and our SEC filings for more detail concerning factors that could cause the actual results to differ materially. In addition, on today's call, non-GAAP financial measures will be used to help investors understand factors' ongoing business performance. A reconciliation of certain non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in the accompanying investor presentation and available in our earnings release issued this morning, which are both available on our website.
請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以取得可能導致實際結果與預期有重大差異之因素的更多細節。此外,在今日電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解影響持續性業務表現的因素。今日討論之部分非 GAAP 財務衡量指標與可比 GAAP 財務衡量指標之調節表,已收錄於隨附的投資人簡報中,並可在我們今早發布的財報新聞稿中取得;兩者皆可於我們網站查閱。
As a reminder, continuing operations excludes Baxter's Kidney Care business and Baxter's former BioPharma Solutions business, which are both reported as discontinued operations.
提醒各位,持續營運不包含百特的腎臟照護(Kidney Care)業務及百特先前的 BioPharma Solutions 業務;兩者皆列為終止營運。
During the Q&A session this morning, Brent, Heather, Joel, and I will be available to address questions. Questions on the results and outlook will be addressed by me and Joel.
在今天上午的問答環節中,Brent、Heather、Joel 與我都將在場回答問題。關於業績與展望的問題將由我與 Joel 回答。
Now I'd like to turn the call over to Brent. Brent?
現在我想把電話交給 Brent。Brent?
Brent Shafer - Chair and Interim Chief Executive Officer
Brent Shafer - Chair and Interim Chief Executive Officer
Thank you, Clare, and good morning, everyone. I appreciate you joining us. As you know, I've recently stepped into the role of Chair and Interim CEO at Baxter. Joe Almeida led the business through a period of significant evolution over his nine-year tenure, and we're sincerely grateful for his dedication to the company.
謝謝你,Clare,各位早安。感謝各位參與。如各位所知,我最近接任百特董事長兼臨時執行長一職。Joe Almeida 在其九年的任期內帶領公司經歷顯著的演進,我們由衷感謝他對公司的投入與奉獻。
One of the Board's top priorities, of course, is the identification of a permanent CEO. The Board is actively engaged in the search process with the support of the leading firm, evaluating both internal and external candidates.
董事會的首要任務之一,當然是尋找一位正式的執行長。董事會在頂尖顧問公司的協助下,正積極投入搜尋流程,同時評估內部與外部候選人。
We're moving expeditiously, but most importantly, we're taking a rigorous approach to ensure we identify the right candidate to lead Baxter into the future. During the transition period, I'm committed to helping ensure we remain focused on crisp execution of our priorities and delivering strong consistent results.
我們正加速推進,但更重要的是,我們採取嚴謹的方法,以確保找出能帶領百特邁向未來的合適人選。在過渡期間,我致力於協助確保我們持續聚焦於優先事項的精準執行,並交付強勁且一致的成果。
I'm pleased to be working with the entire leadership team on these shared goals. We're continuing to move the company forward into a new era and has recently announced that we closed the sale of Vantive on January 31, 2025. This significant milestone was the final step of three strategic actions outlined in January of 2023 to transform the business.
我很高興能與整個領導團隊共同努力,達成這些共同目標。我們持續推動公司邁入新時代,並且近期宣布已於 2025 年 1 月 31 日完成 Vantive 的出售交易。這項重要里程碑,是我們在 2023 年 1 月提出、用以轉型業務的三項策略行動中的最後一步。
You'll recall these actions included the implementation of a new verticalized operating model. As a Director and in my role as Interim CEO, I can confirm that this segment-driven approach has created increased focus and execution related benefits, bringing greater clarity and agility to how we pursue opportunities globally.
各位應該記得,這些行動包括導入新的垂直化營運模式。身為董事並在我擔任臨時執行長的角色中,我可以確認,這種以事業部為驅動的做法帶來更高的聚焦與執行效益,使我們在全球追求機會時更具清晰度與敏捷性。
And as part of our transformation efforts, we completed the divestiture of Baxter's non-core BioPharma Solutions business in 2023. Since joining Baxter's Board in 2022, I've observed and supported these shifts in the company's strategic direction, and I'm extremely proud of the hard work and dedication of our teams to reach this stage. These actions have positioned Baxter to accelerate innovation for patients and customers and to drive profitable growth for our shareholders.
此外,作為轉型努力的一部分,我們已於 2023 年完成出售百特非核心的 BioPharma Solutions 業務。自 2022 年加入百特董事會以來,我觀察並支持公司策略方向的這些轉變,對我們團隊為達成此階段所付出的辛勤努力與投入感到非常自豪。這些行動使百特得以加速為病患與客戶創新,並為股東帶來獲利性成長。
Later in this call, Joel will provide details on our quarterly and full-year performance as well as our outlook for 2025. As you have seen in this morning's release, we finished 2024 on a high note, meeting our fourth-quarter guidance for continuing operations on both the top and bottom lines. And we're starting 2025 building on positive momentum.
在本次電話會議稍後,Joel 將提供我們季度與全年表現的細節,以及我們對 2025 年的展望。如各位今早在新聞稿中所見,我們以亮眼表現結束 2024 年,在持續營運方面,第四季的營收與獲利(上、下線)皆達成指引。而我們也以正向動能展開 2025 年。
During this interim period, I'll be working closely with Heather, Joel, and the rest of Baxter's strong leadership team to ensure we maintain that momentum. I've been very impressed by what I've experienced in the last few weeks: engaged, talented, and highly motivated team that is squarely focused on Baxter's mission to save and sustain lives, a truly collaborative spirit and an intense focus on delivering on our commitments.
在這段臨時期間,我將與 Heather、Joel 以及百特其他強大的領導團隊密切合作,確保我們維持這股動能。過去幾週我所見所聞令我印象深刻:一支投入、才華洋溢且高度有動力的團隊,專注於百特「拯救並延續生命」的使命;真正的協作精神,以及對履行承諾的高度專注。
This includes initiatives focused on innovation and profitable growth to enhance performance, deliver increased value, and to better serve the needs of our patients and customers. To support these efforts and as we've shared earlier this month, we've instituted a new Chief Operating Officer position as a next step in leveraging the potential of our vertical operating model.
這包括聚焦於創新與獲利性成長的各項倡議,以提升績效、創造更高價值,並更好地滿足病患與客戶的需求。為支持這些努力,且如我們本月稍早所分享,我們設立了新的營運長職位,作為進一步發揮垂直營運模式潛力的下一步。
We're fortunate to have Heather Knight step into this role as COO. Heather brings extensive experience and a proven track record to this position after a successful tenure as head of our largest segment, Medical Products & Therapies, among other key leadership roles at Baxter and prior large healthcare companies.
我們很幸運由 Heather Knight 出任營運長(COO)。Heather 在擔任我們最大事業部 Medical Products & Therapies 的負責人期間表現出色,並曾在百特及其他大型醫療保健公司擔任多項關鍵領導職務,為此職位帶來豐富經驗與經過驗證的卓越績效。
She'll be leading day-to-day operations across our three segments, encompassing global commercial operations, R&D supply chain, medical and regulatory affairs. Her leadership will be critical as we navigate the next phase of growth.
她將領導我們三大事業部的日常營運,涵蓋全球商業營運、研發、供應鏈、醫療事務與法規事務。在我們邁向下一階段成長之際,她的領導將至關重要。
Now, I'd like to turn it over to Heather to share her perspective. Heather?
現在,我想把時間交給 Heather,請她分享她的觀點。Heather?
Heather Knight - Executive Vice President, Chief Operating Officer
Heather Knight - Executive Vice President, Chief Operating Officer
Thank you, Brent, and good morning, everyone. I'm very pleased to be joining today's call. I look forward to building upon what we've achieved to date and helping to launch a new chapter of accelerated performance for the company. As Brent mentioned, over the last two years, I've had the privilege of leading Medical Products & Therapies, or MPT, which is Baxter's largest segment with over $5 billion in sales and operations spanning the globe.
謝謝你,Brent,各位早安。我很高興能參與今天的電話會議。我期待在目前成果的基礎上再接再厲,並協助公司開啟加速提升績效的新篇章。如 Brent 所提,過去兩年我有幸領導 Medical Products & Therapies(MPT),這是百特最大的事業部,銷售額超過 50 億美元,營運遍及全球。
During this time, I spearheaded numerous vital initiatives with the support of my talented colleagues including the recent successful launch of our Novum IQ infusion pump platform in the United States. As the leader of NPT, I also helped oversee the North Cove recovery efforts following Hurricane Helene. Given the essential nature of the products that are manufactured in North Cove, we spared no expense in our efforts to help address product supply for patients and customers, including importing products from Baxter sites globally.
在此期間,在我才華洋溢的同事支持下,我主導了多項關鍵倡議,包括近期在美國成功推出我們的 Novum IQ 輸注幫浦平台。作為 NPT 的領導者,我也協助監督了颶風 Helene 之後的 North Cove 復原工作。鑑於 North Cove 所製造產品的關鍵性,我們在協助解決病患與客戶的產品供應方面不惜成本,包括自百特全球各據點進口產品。
Thanks to the incredible dedication and resilience of the North Cove and broader Baxter teams, we were able to reach our production on eight of the site's 10 manufacturing lines in the fourth quarter. Our final two manufacturing lines came online in January, and I'm very proud to report that we are now producing at pre-hurricane levels.
多虧 North Cove 團隊以及更廣泛的 Baxter 團隊展現出令人敬佩的投入與韌性,我們在第四季已能讓該廠區 10 條製造產線中的 8 條達到生產水準。最後兩條製造產線已於 1 月上線,我也非常自豪地報告,我們目前的產量已回到颶風前的水準。
This is just another critical milestone in our recovery as we continue to work to replenish inventory and support our customers and patients' needs. Additionally, I've served as the lead interface to many of our key customers and have been deeply involved and successfully renegotiating the recent renewals of select US GPO contracts, helping to ensure we continue to meet our customers' needs while also delivering positive movement in pricing.
這是我們復原進程中的另一個關鍵里程碑,因為我們持續努力補充庫存並支援客戶與病患的需求。此外,我也擔任多家關鍵客戶的主要對接窗口,並深度參與且成功重新協商部分美國 GPO 合約的近期續約,協助確保我們持續滿足客戶需求,同時也在價格方面帶來正向改善。
As COO, I'm excited to build upon my deep knowledge and understanding of our markets and operations to enhance collaboration across our segments and create a more holistic Baxter experience for our customers and the patients they serve.
作為營運長(COO),我很期待運用我對市場與營運的深厚知識與理解,強化各事業部之間的協作,為客戶及其所服務的病患打造更整體一致的 Baxter 體驗。
I'm confident that by harnessing our combined strength and expertise, we can unlock significant value and accelerate our efforts to drive customer-inspired innovation for all of our stakeholders. I look forward to partnering with Brent, Joel, and the entire Baxter team as we work to achieve our strategic objectives and deliver exceptional results.
我相信,透過整合我們的綜合實力與專業能力,我們能釋放可觀價值,並加速推動以客戶啟發的創新,造福所有利害關係人。我期待與 Brent、Joel 以及整個 Baxter 團隊攜手合作,共同達成策略目標並交出卓越成果。
I'll now turn it over to Joel to discuss our financial performance in more detail. Joel?
接下來我把時間交給 Joel,請他更詳細說明我們的財務表現。Joel?
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
Thanks, Heather, and good morning, everyone. I'm happy to be joining the call this morning to provide some additional details on Baxter's fourth-quarter and full-year 2024 financial performance as well as commentary on our financial outlook for 2025.
謝謝你,Heather,各位早安。很高興今天早上能加入這通電話會議,提供 Baxter 2024 年第四季與全年財務表現的更多細節,並就我們 2025 年的財務展望提出說明。
As Brent mentioned, we are very pleased with our fourth-quarter results and how we ended the year. Our results came in ahead of our prior guidance on both the top and bottom lines, driven by better-than-expected sales and solid operational performance.
如 Brent 所提到的,我們對第四季的結果以及年末收官表現感到非常滿意。在營收與獲利兩端,我們的結果都優於先前指引,主要受惠於優於預期的銷售表現與穩健的營運執行。
Fourth-quarter 2024 global sales from continuing operations of $2.75 billion, increased 1% on a reported basis and 2% on a constant currency basis, and compared favorably to our previous guidance, which called for sales to decline in low-single digits.
2024 年第四季持續營運的全球銷售額為 27.5 億美元,以報告基礎計成長 1%,以固定匯率基礎計成長 2%,且優於我們先前的指引;先前指引預期銷售將呈現低個位數下滑。
Our performance in the quarter was broad-based and reflected positive sales across most of our product divisions. As expected, during the fourth quarter, Hurricane Helene that negatively impacted our sales by approximately $110 million or approximately 400 basis points. Although the overall magnitude is less than the previously anticipated approximately $150 million, given the company's swift recovery efforts.
本季表現涵蓋面廣,反映我們多數產品事業部的銷售皆呈正成長。如預期,第四季颶風 Helene 對我們銷售造成約 1.10 億美元、約 400 個基點的不利影響。由於公司迅速推動復原工作,整體影響幅度低於先前預估的約 1.50 億美元。
For the full year, Baxter reported sales from considered operations at $10.6 billion, increasing 3% on both the reported and constant currency basis. Hurricane Helene negatively impacted growth for the full year by just over 100 basis points. On the bottom line, fourth-quarter adjusted earnings per share from continuing operations were $0.58 and came in ahead of our prior guidance of $0.50 to $0.53 per share, driven by the favorable half-life results and solid operational performance.
就全年而言,Baxter 持續營運的銷售額為 106 億美元,以報告基礎與固定匯率基礎計皆成長 3%。颶風 Helene 對全年成長造成略高於 100 個基點的不利影響。在獲利端,第四季持續營運的調整後每股盈餘為 0.58 美元,優於我們先前每股 0.50 至 0.53 美元的指引,主要受惠於有利的 half-life 結果以及穩健的營運表現。
In addition, our tax rate came in favorable to our expectations, which offset a negative impact from foreign exchange. On a year-over-year basis, adjusted earnings per share from continuing operations declined 11% in the quarter, primarily due to the negative impact of Hurricane Helene on our results.
此外,我們的稅率也優於預期,抵銷了外匯帶來的不利影響。以年對年來看,本季持續營運的調整後每股盈餘下滑 11%,主要是颶風 Helene 對我們業績造成負面影響。
For the full year, adjusted earnings per share from continuing operations totaled $1.89 per share and increased 11% over the prior year, reflecting solid underlying operational performance and a benefit from non-operational items, including lower interest expense and tax rate.
就全年而言,持續營運的調整後每股盈餘合計為每股 1.89 美元,較前一年成長 11%,反映穩健的核心營運表現,以及非營運項目的助益,包括利息費用降低與稅率下降。
Now I'll walk through our results for our reportable segments. Commentary regarding sales growth will reflect growth at constant currency rates. Sales in our Medical Products & Therapies, or MPT segment were $1.3 billion, increasing 1% in the quarter and coming in favorable to expectations.
接下來我將說明各可報告事業部的表現。關於銷售成長的評論,將以固定匯率口徑呈現。我們醫療產品與治療(Medical Products & Therapies,MPT)事業部本季銷售額為 13 億美元,成長 1%,且優於預期。
Full-year 2024 sales totaled $5.2 billion, advancing 5% and ahead of the prior guidance of 2% to 3% growth. Adjusting for the impact of (inaudible), MPT sales growth in the quarter would have been approximately 9% and approximately 7% for the full year. Within NPT, fourth-quarter sales from our Infusion Therapies & Technologies division totaled $1.0 billion and decreased 1%. Sales in the quarter benefited from significant growth for our US infusion systems portfolio as the rollout of our Novum IQ pub platform continues to build momentum with orders coming in from both new and existing customers.
2024 年全年銷售額合計為 52 億美元,成長 5%,高於先前指引所預期的 2% 至 3% 成長。若調整(聽不清楚)的影響,MPT 本季銷售成長約為 9%,全年約為 7%。在 NPT 之內,我們輸注治療與技術(Infusion Therapies & Technologies)事業部第四季銷售額為 10 億美元,下滑 1%。本季銷售受惠於美國輸注系統產品組合的顯著成長,因為我們 Novum IQ pub 平台的推廣持續累積動能,來自新客戶與既有客戶的訂單皆持續增加。
Nutrition sales in the quarter advanced double digits globally reflecting the strength in the US as we continue to build out our alternate site portfolio. Finally, as anticipated, IV Solutions declined in the quarter due to the impact of Hurricane Helene.
本季營養產品(Nutrition)在全球呈現雙位數成長,反映美國市場的強勁表現,因我們持續擴充替代照護場域(alternate site)產品組合。最後,如先前預期,IV Solutions 因颶風 Helene 的影響而在本季下滑。
Q4 sales of Advanced Surgery totaled $292 million and grew 6% globally. Results in the quarter reflected solid demand and positive pricing for our portfolio of (inaudible) and sealant across the globe. MPT's adjusted operating margin for the quarter was 15.5%, coming in better than expected due to the sales outperformance.
第四季先進外科(Advanced Surgery)銷售額為 2.92 億美元,全球成長 6%。本季結果反映我們(聽不清楚)與封合劑(sealant)產品組合在全球的穩健需求與正向定價。MPT 本季調整後營業利益率為 15.5%,由於銷售優於預期而表現好於預估。
Margins declined year over year, primarily reflecting the impact of the hurricane. In Healthcare Systems & Technologies, or HST, sales in the quarter were in line with expectations and totaled $784 million decreasing 1%. Full-year 2024 sales totaled $3 billion and declined 2%. Within the HST segment, sales in the quarter for our Care & Connectivity Solutions, or CCS division were $504 million, advancing 3% globally.
利潤率年對年下滑,主要反映颶風的影響。在醫療照護系統與技術(Healthcare Systems & Technologies,HST)方面,本季銷售符合預期,為 7.84 億美元,下滑 1%。2024 年全年銷售額為 30 億美元,下滑 2%。在 HST 事業部內,我們照護與連結解決方案(Care & Connectivity Solutions,CCS)事業部本季銷售額為 5.04 億美元,全球成長 3%。
Performance in the quarter was driven by 9% growth in the US for CCS due to continued momentum in our Patient Support Systems or PSS business, which once again delivered strong growth and reflected a benefit from competitive wins in both our [med search] and ICU product lines as well as upgrades for existing customers.
本季表現主要由 CCS 在美國成長 9% 所帶動,原因是我們病患支援系統(Patient Support Systems,PSS)業務動能延續,再次交出強勁成長,並受惠於在 [med search] 與 ICU 產品線的競爭性勝出,以及既有客戶的升級需求。
Total US capital orders for CCS rose 9% in the quarter and increased 15% for the full year. We are exiting the year with a healthy backlog and strong funnel. [And want] to build a positive momentum over the course of 2025. Performance for this division was partially offset by weaker sales outside the US, reflecting a difficult comparison to the prior year period. We saw growth of 12% as well as softness in both China and France in the current year.
CCS 在美國的資本設備訂單本季成長 9%,全年成長 15%。我們在年末擁有健康的在手訂單(backlog)與強勁的商機管道(funnel),並希望在 2025 年持續累積正向動能。該事業部的表現部分被美國以外較疲弱的銷售所抵銷,主要反映與前一年同期相比基期較高。本年度我們看到 12% 的成長,同時在中國與法國也出現疲弱。
Front Line Care sales in the quarter were $280 million and declined 8%. Consistent with commentary over the course of this year, performance in the quarter was impacted by the backlog reductions, which positively contributed to sales in the prior year period. Results in the quarter also reflected the impact of certain market exits and supply constraints, which collectively impacted sales by approximately $15 million in the quarter. We expect the supply constraints that impacted the fourth quarter to be largely resolved for most products in the first quarter of 2025.
第一線照護(Front Line Care)本季銷售額為 2.80 億美元,下滑 8%。如同我們今年以來的說明,本季表現受到在手訂單消化(backlog reductions)的影響;該因素在前一年同期對銷售有正向貢獻。本季結果亦反映部分市場退出與供應限制的影響,兩者合計使本季銷售約減少 1,500 萬美元。我們預期影響第四季的供應限制,對多數產品而言將在 2025 年第一季大致獲得解決。
We believe that performance for this division will also benefit from stabilization in the primary care market over the course of 2025 as well as the launch of (inaudible) products in the second half of this year that are expected to contribute to positive performance for FLC in 2025 and beyond. [HST] fourth-quarter adjusted operating margins of 18.5% increased sequentially, continuing the trend of sequential margin improvements.
我們認為,該事業部的表現也將受惠於 2025 年期間基層照護市場的趨於穩定,以及今年下半年推出的(聽不清楚)產品;預期這些因素將在 2025 年及其後為 FLC 帶來正向表現。
Margins declined year over year, primarily reflecting higher investments. Moving on to our Pharmaceutical segment. Sales in the quarter came in favorable to expectations and totaled $643 million, increasing 8%. Full-year 2024 sales were $2.4 billion, advancing at 7%. Fourth-quarter sales with Injectable & Anesthesia of $383 million grew 8%.
毛利率年對年下滑,主要反映投資增加。接下來談我們的製藥事業部。本季銷售表現優於預期,合計為6.43億美元,成長8%。2024全年銷售為24億美元,成長7%。第四季注射劑與麻醉產品銷售為3.83億美元,成長8%。
Performance in the quarter reflected mid-teens growth in our specialty injectables portfolio, an anticipated rebound from the third quarter, which was impacted by the timing of some orders. Growth was driven by strong demand for US premixed products and the continued rollout of new products as well as the benefit from targeted sales and marketing initiatives that have been implemented.
本季表現反映我們專科注射劑產品組合達到約十幾%的成長,符合預期,並自第三季回升;第三季受部分訂單時點影響。成長動能來自美國預混產品的強勁需求、持續推出新產品,以及已推動之精準銷售與行銷措施所帶來的效益。
As expected, lower sales of [inhaled] anesthesia, which declined mid-single digits, slightly tempered overall performance for the injectables and anesthesia. Within drug compounding, continued demand for services resulted in strong growth of 9% for the quarter.
如預期,[吸入式]麻醉產品銷售較低(下滑約中個位數百分比),使注射劑與麻醉整體表現略受抑制。在藥品調配(drug compounding)方面,服務需求持續,使本季實現9%的強勁成長。
Pharmaceutical adjusted operating margins were 15.9% for the quarter increasing 600 basis points sequentially. Adjusted operating margins decreased 370 basis points compared to the prior year, reflecting the impact from the MSA entered into following the BPS sales and increased operating expenses to support the new and upcoming launches.
製藥事業部本季調整後營業利益率為15.9%,較前一季提升600個基點。相較去年同期,調整後營業利益率下降370個基點,反映在BPS出售後所簽訂MSA的影響,以及為支援新產品與即將上市產品而增加的營運費用。
The pharmaceuticals team remains focused on expanding margins through improved mix, stabilizing the anesthesia business, driving cost improvements, compounding business, and executing our margin improvement initiatives in the integrated supply chain.
製藥團隊仍聚焦於透過改善產品組合、穩定麻醉業務、推動成本改善、發展調配業務,以及在整合式供應鏈中執行我們的利潤率改善計畫,以擴大利潤率。
Other sales, which represent sales not allocated to those segments and primarily include sales and products and services provided directly to certain of our manufacturing facilities were $12 million in the quarter and totaled $67 million for full-year 2024.
其他銷售(代表未分配至各事業部之銷售,主要包括直接提供給部分製造設施的產品與服務)本季為1,200萬美元,2024全年合計為6,700萬美元。
Before moving on to the rest of the P&L results, I wanted to make some comments regarding our continuing operations as reported going forward. I mentioned last quarter, due to the change of moving Kidney Care business results to discontinued operations, corporate costs that have previously been allocated to the Kidney Care segment that would not convey with the Kidney Care business in the sale are now reported in unallocated corporate costs.
在進入其餘損益表(P&L)結果之前,我想就未來將揭露的持續營運(continuing operations)做一些說明。我在上季提到,由於腎臟照護(Kidney Care)業務結果改列為停業單位(discontinued operations),先前分攤至腎臟照護事業部、且在出售時不會隨該業務移轉的公司成本,現改列為未分配公司成本(unallocated corporate costs)。
As we previously commented, we plan to offset a large portion of these expenses in 2025 through income to be received from Vantive under the transition services agreements, or TSAs, as well as cost containment initiatives the company is already in the process of undertaking.
如先前所述,我們計畫在2025年透過依轉型服務協議(transition services agreements,TSA)自Vantive取得的收入,以及公司已在推動的成本控管措施,來抵銷其中大部分費用。
Our goal remains to fully offset the impact of stranded costs and the loss of TSA income by the end of 2027. Fourth-quarter adjusted gross margin from continuing operations was 44.5%, coming in favorable to expectations and reflecting a sequential improvement of 80 basis points.
我們的目標仍是在2027年底前,完全抵銷擱置成本(stranded costs)影響以及TSA收入消失的影響。第四季持續營運的調整後毛利率為44.5%,優於預期,並較前一季改善80個基點。
On a year-over-year basis, adjusted gross margins declined slightly by 10 basis points driven primarily by the impact of Hurricane Helene, higher spend within (inaudible) manufacturing plants to support product growth as well as the impact of the manufacturing supply agreement following the sale of BPS.
以年對年來看,調整後毛利率小幅下降10個基點,主要受颶風Helene影響、(聽不清)製造廠為支援產品成長而增加支出,以及BPS出售後製造供應協議的影響所致。
Positive contributors to margin in the quarter were ongoing benefits from our margin improvement programs within our integrated supply chain network as well as favorable product mix and pricing initiatives in select markets. Adjusted gross margin from continuing operations for the year totaled 43.5%.
本季利潤率的正面貢獻包括:我們整合式供應鏈網路中利潤率改善計畫的持續效益,以及部分市場有利的產品組合與定價措施。全年持續營運的調整後毛利率合計為43.5%。
Fourth-quarter adjusted SG&A from contingent operations totaled $679 million or 24.7% as a percentage of sales, an increase of 190 basis points from the prior year period as we continue to make select investments to support our growth objectives and new product launches. This increase also included approximately $30 million of select discrete items that are not expected to repeat, including increased employee healthcare expenses due to high-cost medical claims incurred during the quarter, fees associated with our tax optimization program, and phasing of stock compensation expenses.
第四季持續營運的調整後銷售、一般及行政費用(SG&A)合計為6.79億美元,占銷售額24.7%,較去年同期增加190個基點;我們持續進行選擇性投資,以支援成長目標與新產品上市。此增幅亦包含約3,000萬美元的特定一次性項目,預期不會重複發生,包括:因本季發生高額醫療理賠而增加的員工醫療保健費用、與稅務最佳化計畫相關的費用,以及股票薪酬費用的時點分攤。
These higher expenses were offset by benefits from lower stranded costs. Full-year 2024 adjusted SG&A totaled $2.66 billion and represented 25% of sales. Adjusted R&D spending from continuing operations in the quarter totaled $131 million and represented 4.8% as a percentage of sales, an increase of 10 basis points compared to the prior year period, and reflects our continued investments in advancing new products across the portfolio and bringing innovation to patients across our segments.
上述較高費用部分被擱置成本降低所帶來的效益抵銷。2024全年調整後SG&A合計為26.6億美元,占銷售額25%。本季持續營運的調整後研發(R&D)支出合計為1.31億美元,占銷售額4.8%,較去年同期增加10個基點,反映我們持續投資推進產品組合中的新產品,並在各事業部為病患帶來創新。
2024 full-year adjusted R&D totaled $510 million or 4.8% as a percent of sales. These factors resulted in an adjusted operating margin of 15.2% on a continuing operations basis, coming in favorable expectations and improving 70 basis points sequentially. Compared to the prior year, adjusted operating margins from continued operations decreased 190 basis points, driven by the factors I just discussed as well as the unfavorable impact from foreign exchange.
2024全年調整後研發合計為5.10億美元,占銷售額4.8%。上述因素使持續營運基礎的調整後營業利益率達15.2%,優於預期,並較前一季改善70個基點。相較去年,持續營運的調整後營業利益率下降190個基點,除我剛提到的因素外,亦受外匯不利影響所致。
Full-year 2024 adjusted operating margin from continuing operations was approximately $1.5 billion or 13.9% of sales. Net interest expense from continuing operations totaled $90 million in the quarter, an increase of $18 million versus the prior year period, reflecting lower interest income.
2024全年持續營運的調整後營業利益約為15億美元,占銷售額13.9%。本季持續營運的淨利息費用為9,000萬美元,較去年同期增加1,800萬美元,反映利息收入降低。
For the full year, net interest expense totaled $341 million, decreasing $98 million and reflecting the benefit of our debt repayment initiatives. Adjusted other non-operating income totaled $4 million in the quarter compared to income of $10 million in the prior year period. For the full year, adjusted other non-operating income that continue operations tax rate was 17.5%, both the full-year and fourth-quarter tax rates reflect the benefit of initiatives we have undertaken to optimize our global tax rate.
全年淨利息費用合計為3.41億美元,減少9,800萬美元,反映我們償債措施帶來的效益。本季調整後其他非營業收入為400萬美元,去年同期為1,000萬美元。全年方面,持續營運的調整後其他非營業收入之稅率為17.5%;全年與第四季稅率皆反映我們為最佳化全球有效稅率所採取措施的效益。
And as previously mentioned, adjusted earnings from continuing operations were $0.58 per share for the quarter and decreased 11% versus the prior year. Positive contributions to earnings included improved commercial performance from new product launches and positive pricing. In the quarter, these drivers were offset by the negative impact of Hurricane Helene, which we estimate impacted our results by approximately $0.10 per share and an unfavorable impact from foreign exchange and interest expense of approximately $0.06 per share.
如先前所述,本季持續營運的調整後每股盈餘為0.58美元,較去年下降11%。盈餘的正面貢獻包括新產品上市帶來的商業表現改善與正向定價。本季上述動能被颶風Helene的負面影響所抵銷;我們估計其對結果的影響約為每股0.10美元,另有外匯與利息費用的不利影響約每股0.06美元。
Full-year 2024 adjusted earnings per share from continuing operations totaled $1.89 per share, an increase of 11% as compared to the prior year period. Let me conclude my remarks by discussing our outlook for the full year of 2025 and the first quarter of 2025, including some key assumptions underpinning the guidance. All guidance provided excludes the impact of Kidney Care discontinued operations.
2024全年持續營運的調整後每股盈餘合計為每股1.89美元,較去年同期增加11%。最後,我將以討論2025全年與2025年第一季展望作結,並說明支撐指引的若干關鍵假設。所有提供的指引均不包含腎臟照護停業單位的影響。
For full-year 2025, Baxter expects total sales growth of 5% to 6% on a reported basis. This guidance includes an approximate 200 basis points negative impact from foreign exchange based on current rates as well as approximately $345 million of anticipated MSA revenues from Vantive.
就2025全年而言,Baxter預期以報導基礎(reported basis)計算的總銷售成長為5%至6%。此指引包含依目前匯率估算之外匯約200個基點的負面影響,以及預期自Vantive取得約3.45億美元的MSA收入。
Operationally, Baxter expects sales to grow 4% to 5%. This guidance excludes the impact of foreign exchange, MSA revenues, and the planned exit of IP solutions from China as the company continues to focus on driving profitable growth. The negative impact from exiting the IV Solutions business in China is approximately 50 basis points to growth.
以營運面(operationally)而言,Baxter預期銷售成長為4%至5%。此指引排除外匯、MSA收入,以及公司為持續聚焦推動獲利成長而計畫退出中國IP solutions業務的影響。退出中國IV Solutions業務對成長的負面影響約為50個基點。
Operational sales guidance for the full year by reportable segment is as follows: for MPT, we expect sales to increase approximately 5%, driven by continued momentum in our Novum LVP launch, the benefit of positive pricing in the US, and other underlying business from Baxter. This guidance excludes the impact of exiting the IV Solutions market in China, which is estimated to impact sales growth by 120 basis points.
按可申報分部劃分之全年營運銷售指引如下:就 MPT 而言,我們預期銷售將成長約 5%,主要受惠於 Novum LVP 上市持續帶動的動能、美國正向定價帶來的效益,以及來自 Baxter 的其他基礎業務。此指引不包含退出中國 IV Solutions 市場的影響;該退出預估將使銷售成長率減少 120 個基點。
Sales in our HST segment are expected to increase approximately 3% and is expected to be balanced across both CCS and FLC. We expect Pharmaceuticals to increase approximately 5% to 6% and driven by mid-single-digit growth in both specialty injectables and drug compounding.
我們 HST 分部的銷售預期將成長約 3%,且預期在 CCS 與 FLC 之間大致均衡。我們預期製藥業務將成長約 5% 至 6%,主要由專科注射劑與藥品調配兩者的中個位數成長所帶動。
Now I'll turn to our outlook for other P&L line items. As previously shared, we expect full-year adjusted operating margin from continuing operations to total approximately 16.5% and includes TSA income of approximately $125 million. We expect our non-operating expenses, which include net interest expense and other income and expense to total between $250 million to $270 million. On a continued operations basis, we anticipate a full-year tax rate of approximately 19.5%.
接下來我將談談其他損益表(P&L)項目的展望。如先前所分享,我們預期來自持續營運的全年調整後營業利益率約為 16.5%,其中包含約 1.25 億美元的 TSA 收入。我們預期非營運費用(包含淨利息費用及其他收入與費用)合計約為 2.5 億至 2.7 億美元。以持續營運為基礎,我們預估全年稅率約為 19.5%。
We expect our diluted share count to average approximately 55 million shares for the year, which does not contemplate any share repurchases. Based on all these factors, we now anticipate full-year adjusted earnings on a continuing operations basis, of $2.45 to $2.55 per diluted share. This outlook includes an estimated negative impact of approximately $0.03 per share from foreign exchange based on current rates.
我們預期全年稀釋後流通股數平均約 5,500 萬股,未納入任何庫藏股回購。綜合上述因素,我們目前預期以持續營運為基礎的全年調整後每股盈餘為每股稀釋後 2.45 至 2.55 美元。此展望包含依目前匯率估算之外匯帶來的每股約 0.03 美元負面影響。
A couple of other quick comments I'd like to make regarding our outlook for 2025. First, I'd point out that our current guidance includes a slight impact from tariffs enacted in China but does not reflect any impact from potential tariffs that are contemplated for Mexico and Canada, given the fluidity of the situation and potential for further delays implementation and possible exemptions.
關於我們對 2025 年展望,還有幾點簡短補充。首先,我要指出,我們目前的指引已包含中國已實施關稅帶來的些微影響,但鑑於情勢仍在變動、可能進一步延後實施以及可能豁免,並未反映對墨西哥與加拿大可能考量之關稅影響。
Second, in 2024, (inaudible) has previously been allocated to Kidney Care that did not convey with the discontinued operations presentation were reported in unallocated corporate costs. Starting in 2025, these costs will be allocated to the three segments, along with related TSA income. Specifics in the first quarter of 2025, we expect continued operational sales growth of approximately 3% to 4% on a reported basis, and approximately 4% on an operational basis.
第二,於 2024 年,(聽不清)先前分攤至 Kidney Care、但未隨停業營運呈列一併移轉的項目,係列報於未分攤之公司成本。自 2025 年起,這些成本將分攤至三個分部,並連同相關 TSA 收入一併分攤。具體而言,在 2025 年第一季,我們預期以報告基礎計算之持續營運銷售成長約 3% 至 4%,以營運基礎計算約為 4%。
For the first quarter, foreign exchange is expected to negatively impact the top line by more than 200 basis points and MSA revenues are expected to total approximately $60 million. The China IV Solutions exit is expected to impact top-line growth by approximately 60 basis points in the first quarter.
就第一季而言,外匯預期將使營收端(top line)產生超過 200 個基點的負面影響,MSA 收入預期合計約 6,000 萬美元。退出中國 IV Solutions 預期將在第一季使營收成長率約減少 60 個基點。
On a continuing operations basis, we expect adjusted earnings per share of $0.47 to $0.50 per share. This guidance reflects the impact of closing Vantive on January 31, which negatively impacted earnings per share by approximately $0.04 in the quarter as compared to the closing of the sale on December 31, had we been able to close on that date.
以持續營運為基礎,我們預期調整後每股盈餘為每股 0.47 至 0.50 美元。此指引反映 1 月 31 日完成 Vantive 交易結案的影響;相較於若能於 12 月 31 日完成出售結案,本季每股盈餘約減少 0.04 美元。
With that, we can now open up the call for Q&A.
接下來,我們現在可以開放問答。
Operator
Operator
(Operator Instructions) I would like to remind the participants that this call is being recorded, and a digital replay will be available on the Baxter International website for 60 days at www.baxter.com.
(接線員指示)提醒各位與會者,本次電話會議將被錄音,並將於 Baxter International 網站提供 60 天的數位重播,網址為 www.baxter.com。
Robbie Marcus, JPMorgan.
JPMorgan 的 Robbie Marcus。
Robert Marcus - Analyst
Robert Marcus - Analyst
Thank you for taking the questions. Two for me. First, Joel, how should we think about, with all the moving pieces on the top and bottom line the cadence for 2025?
謝謝讓我提問。我有兩個問題。第一個,Joel,面對營收端與獲利端的各種變動因素,我們應該如何看待 2025 年的節奏(cadence)?
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
Sure. Robbie, thanks for the question. So I'll start off with sales line. And as you know, we normally have some ramp in our business over the course of the year, but there's a couple of things I'd call up this year. specifically.
好的。Robbie,謝謝你的問題。我先從銷售端談起。如你所知,我們的業務通常在一年當中會逐步爬升,但今年有幾點我想特別提出。
First and foremost is, if the -- I'd say, the first quarter, we're taking a somewhat more conservative approach in the sense that we're still recovering from the hurricane. And so we've given ourselves a little bit I'd say services to see how that all plays out. I'd say despite what should be a relatively easier comp with HST, certainly, there's going to be an (inaudible) asset built into the first quarter from a conservatism standpoint.
首先也是最重要的是,我會說第一季我們採取相對保守的作法,因為我們仍在從颶風影響中復原。因此我們給自己留了一點空間,我會說是留些餘裕來觀察後續發展。我會說,儘管 HST 的比較基期相對較容易,但從保守角度來看,第一季仍會納入一個(聽不清)的因素。
I would say the other thing I would call out over the course of the year is that in the fourth quarter, we do anticipate that being a larger quarter in the sense that obviously, we're comparing up against the impact of lean.
我會說,另一個我想在全年節奏上提出的是,第四季我們確實預期會是較大的一季,因為很明顯我們是在與精實(lean)影響所造成的基期進行比較。
So those are a couple of things that I'd probably call out from a cadence perspective on the top. From an earnings perspective of (inaudible), I think the main thing I'd call out there exactly is that we do anticipate continue to ramp over the course of the year, mostly driven by the impact of our spare cost work that will be kicking in and continued improvements over the course of the year. And so obviously, that's what we've already started to do, but obviously, that will continue to build over the course of the year. And so therefore, we expect some brings perspective for that reason.
以上是我在營收端節奏上大概會提出的幾點。就獲利(聽不清)而言,我認為我會特別指出的重點是,我們確實預期全年將持續逐步提升,主要由我們備品成本(spare cost)相關工作開始發揮效益,以及全年持續改善所帶動。因此,這些工作我們已經開始推動,但顯然會在全年持續累積。因此,基於這個原因,我們預期會呈現一定的逐步改善節奏。
Robert Marcus - Analyst
Robert Marcus - Analyst
Great. Maybe a quick follow up. The HST business, especially Front Line Care, was still negative growth this quarter. What's the latest you're seeing there? The confidence you could turn it around in 2025 in your level of visibility to it?
很好。也許快速追問一下。HST 業務,特別是 Front Line Care,本季仍是負成長。你們目前看到的最新情況如何?你們對於在 2025 年扭轉局面的信心,以及對其可見度(visibility)如何?
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
Yeah. So I'd say a couple of things there. I mean, first of all, we are anticipating a stabilization of the primary care markets. And we certainly have seen some of that are starting to see that even as we head into the first quarter. So I think that obviously had a substantial decline in 2024.
是的。我會說有幾點。首先,我們預期基層醫療市場將趨於穩定。而且我們確實已經看到一些跡象,甚至在邁入第一季時也開始看到。所以我認為該市場在 2024 年確實出現了相當幅度的下滑。
And so from that perspective, I think the stabilization of that market is an important piece of this. Yeah, certainly, we do anniversary some difficult costs over the course of the year, for example, things like (inaudible) some of the things that were again -- so the stimulus (inaudible) just some of the spending things in the backlog, we're up against in '24 versus '23. We don't have those headwinds to the extent that we did, obviously, as we enter to '25. So I think that's another important piece of this.
因此從這個角度來看,該市場的穩定化是其中一個重要環節。是的,全年過程中我們也會度過一些艱難成本的周年比較,例如像(聽不清)以及一些同樣是——因此刺激(聽不清)以及一些積壓中的支出項目,我們在 24 年相較 23 年所面臨的。當我們進入 25 年時,這些逆風不會像先前那樣明顯。所以我認為這也是另一個重要部分。
And then I think some of the things that we called out in the prepared remarks, around some of the supply constraints. I think that's -- we're looking to resolve that, I think by Q1 of this year. And so I think, generally speaking, some of the impacts that we had last year, we won't be up against in the same way this year. And in addition to that, in a little bit of a longer-term perspective, we need to some interesting new product launches that are coming out with that will impact us certainly more later in the year than '26.
另外,我認為我們在事先準備的講稿中提到的一些供應限制。我認為——我們希望在今年第一季前後解決。因此整體而言,我們去年所受到的一些影響,今年不會以同樣方式再度面臨。此外,從稍微更長期的角度來看,我們也有一些有趣的新產品上市即將推出,對我們的影響在今年下半年會比 26 年更為明顯。
That side to the reason we feel confident in that. And I know you asked about FLC, but just from the perspective of CCS as well. One of the other differences this year versus last year was, as you probably ended in the last year with an order book that actually have quite a bit of softness in it. It has an impact in the early part of the year last year. As we've talked about in the second half of this year, our order book in CCS has remained quite strong, particularly PSS US.
這也是我們對此感到有信心的原因之一。我知道你問的是 FLC,但也從 CCS 的角度來看。今年相較於去年另一個差異是,如你所知,去年年底我們的訂單簿其實有相當程度的疲軟。這在去年年初造成了影響。正如我們談到的,今年下半年我們在 CCS 的訂單簿仍然相當強勁,尤其是 PSS US。
And so we hand it to this year with certainly a lot of (inaudible) in that business as well. So I think the combination of those things, Robbie, give us a perspective on why we think there's a good opportunity for some recovery this year on the HST overall.
因此我們帶著該業務中確實相當多的(聽不清)進入今年。所以我認為這些因素的組合,Robbie,讓我們能理解為什麼我們認為今年整體 HST 有不錯的復甦機會。
Robert Marcus - Analyst
Robert Marcus - Analyst
Appreciate it. Thanks a lot.
感謝。非常謝謝。
Operator
Operator
David Roman, Goldman Sachs.
David Roman,高盛。
David Roman - Analyst
David Roman - Analyst
Heather, congratulations on the new role. I'm looking forward to working with you in this capacity. And Clare, thank you and the finance team for the extensive financial information here at super helpful as we look at the company post Vantive. I guess my first question, in the past several years for Baxter have been characterized by exogenous events like Hurricane Helene, elevated inflationary pressures, the transition with the Hill-Rom deal, and the strategic actions you've taken with BPS and Vantive.
Heather,恭喜你擔任新職務。我期待以這樣的身分與你合作。Clare,也謝謝你和財務團隊在這裡提供大量財務資訊,對我們在 Vantive 之後評估公司非常有幫助。我想我的第一個問題是,過去幾年 Baxter 的情況一直受到外生事件影響,例如 Helene 颶風、通膨壓力升高、Hill-Rom 交易的整合轉換,以及你們在 BPS 與 Vantive 上採取的策略行動。
Can you help us think about the direction of the company from here and how you're thinking about strategic priorities and maybe at the same time, give us a flavor for how that fits into the profile and characteristics if you go through the CEO search?
你能否協助我們思考公司接下來的走向,以及你們如何看待策略優先事項;同時也請你談談,在進行 CEO 遴選時,這些如何契合你們所尋找的輪廓與特質?
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
Absolutely. I'll start and then Brent can add and he'd like to on the other piece of that. And obviously, you're right, there certainly has been a lot going on here at Baxter. But what I would say, first of all, we this company has done an amazing job of working through these transformational efforts here over the last couple of years, and it really sets us up in a good place for this company moving forward. And so how do I think about priorities for the company.
當然可以。我先開始,然後 Brent 也可以就另一部分補充他想補充的內容。而且你說得沒錯,Baxter 這裡確實發生了很多事情。但我想先說的是,過去幾年公司在推進這些轉型工作方面做得非常出色,這也讓我們在未來前進時處於很好的位置。那我如何看待公司的優先事項呢。
And again, certainly, we'll roll more on the Capital Markets Day sometime after the new CEO has been named. But we're start -- I would say, it starts with customer inspired innovation. These are things that we and the company want to make sure that we are driving innovative products and opportunities and obviously inspired by our customers.
同樣地,在新 CEO 任命之後的某個時間點,我們會在資本市場日再更完整地說明。但我會說,首先是以客戶啟發的創新。我們與公司希望確保推動創新產品與機會,並且顯然是由客戶所啟發。
We're certainly going to have a focus on targeted markets. I would say it's one of the kind of the growth of the growers. How do we find those opportunities where we can actually invest our capital in place that's ultimately going to drive growth for the organization. I'd say, the third thing really, I think about it is how do we optimize the structure of our company.
我們也會聚焦於特定目標市場。我會說這是所謂「成長中的成長」。我們如何找到那些機會,能把資本投入到最終能帶動組織成長的地方。第三點,我真正會思考的是如何優化公司的架構。
Obviously, with the sale of the kidney business optimizing both our cost structure for the standard strip cost perspective, but also optimizing our supply chain, and some of the things that allow us to take advantage of some of the, I'll call them, more simple supply chain opportunity without having to have our home deliveries in the kidney business. So that's the third thing.
顯然,隨著腎臟業務的出售,我們要從標準化降本(strip cost)的角度優化成本結構,同時也要優化供應鏈;並且讓我們能把握一些我稱之為較為簡單的供應鏈機會,因為不再需要腎臟業務的到府配送。這是第三點。
I'd say fourth is really around this concept of commercial excellence and how do we drive consistent execution as a company, as again, a key focus. The last I'd say is really around disciplined capital allocation. Those things that allow us to both focus on driving growth both organically and again, in a folded tuck-in way inorganically but then also balanced with returning value to shareholders. And so I would call those things really out is how to think about our company moving forward.
第四點是「商業卓越」這個概念,以及我們如何推動公司持續一致的執行力,作為另一個關鍵重點。最後一點是有紀律的資本配置。這些能讓我們一方面專注於推動成長(包括有機成長,以及以更整合式、補強式的方式進行的非有機成長),同時也在回饋股東價值之間取得平衡。因此我會把這些作為我們未來前進時思考公司的重點。
And again, I'll turn it over to Brent in terms of just how does that really fit into the process of the CEO search. Brent?
同樣地,我把話交給 Brent,談談這如何融入 CEO 遴選流程。Brent?
Brent Shafer - Chair and Interim Chief Executive Officer
Brent Shafer - Chair and Interim Chief Executive Officer
Well, I'd just add, in this transition period, certainly, I'm looking for stability, predictable, consistent, strong results. And by Joel, I give tremendous credit to this organization for all the things they have worked through, many of them very complex projects, time consuming. So directionally starting to move the organization to more of an emphasis on growth both through innovation and through commercial execution is in the short term moves we can make that accelerate progress in the company.
我只想補充,在這段過渡期間,我們當然在尋求穩定、可預測、可持續且強勁的成果。而且,Joel,我要高度肯定這個組織在面對並處理所有事情上的表現,其中許多都是非常複雜、耗時的專案。因此在方向上,讓組織更強調成長——透過創新以及商業執行——是我們短期內可以採取、用以加速公司進展的動作。
And as far as CEO search and how we're looking at that at the Board level, that work is already underway. And as you can imagine, there's a pretty good profile of Baxter Baxter's portfolio where we are at this point in time. So the experience that we're looking for would be appropriate with the company's situation and opportunities in front of us.
至於 CEO 遴選以及董事會層級如何看待這件事,相關工作已經在進行中。如你所想像,對於 Baxter 目前所處的階段與其投資組合,我們已有相當清晰的輪廓。因此我們尋找的經驗會與公司當前情況以及眼前的機會相匹配。
So the candidates need to have that experience and a vision that can lead the company forward to its next chapter. And having been here and now been on the Board and just working with this management team, I just think there is phenomenal opportunity here because so much heavy lifting has been done over the last few years to streamline and to put this new vertical organization in place, which I think is a real winner, honestly, it's a great opportunity.
所以候選人需要具備那樣的經驗,以及能帶領公司邁向下一篇章的願景。我在這裡任職過、現在也在董事會,並與這個管理團隊合作,我認為這裡有非常巨大的機會,因為過去幾年已完成大量艱鉅工作來精簡流程並建立新的垂直化組織架構;坦白說,我認為這會是很大的成功,這是一個很棒的機會。
David Roman - Analyst
David Roman - Analyst
And maybe just a quick follow up on the financial side. Joel, can you walk us through the post-Vantive sales capital structure of the company? And just maybe update us on target leverage ratios and the timeframe to achieve that?
另外在財務面快速追問一下。Joel,你能否帶我們了解 Vantive 交易後公司的銷售與資本結構?也請更新一下目標槓桿比,以及達成該目標的時間表?
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
Yeah, absolutely. So maybe I'll start with the leverage ratio. Certainly, what we've talked about we're continue to be committed to is a turn leverage ratio around 3 times net debt to EBITDA. And I think that is a level that give us -- gives us opportunity to both balance strategic investments in the company and as well again return value to shareholders in a way that I think balances out our capital structure.
好的,當然。我先從槓桿比開始。我們一直在強調並持續承諾的是,將槓桿比(淨負債/EBITDA)降到約 3 倍左右。我認為這個水準能讓我們在公司策略性投資與回饋股東價值之間取得平衡,並以我認為能平衡資本結構的方式來進行。
I -- we anticipate that we're able to achieve that term and leverage by the end of 2025, will certainly happen sometime in the later part of the second half of the year. Feel good about that. Obviously, since the deal closed with Vantive, we paid down $3 billion of debt. The first part of this was taking out our delayed drop or loan that we had taken out earlier in 2024. And then we also paid off a portion of about $1 billion with 2026 term load. That was actually our highest compound debt.
我們預期可在 2025 年底前達成該目標槓桿水準,應該會在下半年較後段的某個時間點實現。對此我們很有信心。顯然,自 Vantive 交易完成以來,我們已償還 30 億美元債務。其中第一部分是清償我們在 2024 年稍早取得的延遲提款(delayed draw)貸款。此外,我們也償還了約 10 億美元的 2026 年期貸款的一部分。那其實是我們成本最高的債務。
So I guess I would say between that work and our continued efforts in terms of driving free cash flow out of the organization, I feel comfortable with the fact that we're heading towards that target, that will allow us to get really to adjust our capital allocation priorities from what's mostly paying down debt to those areas that it would allow us to get to invest -- continued investments in driving organic growth, continued opportunities for fold-in tuck-in opportunities will that make sense. And the opportunity to restart a buyback program. Certainly, initially, the offset option dilution, that I would say, opportunistically from there.
因此我會說,透過這些工作,以及我們持續努力提升組織的自由現金流,我對我們正朝向該目標前進感到放心;這也將使我們能把資本配置的優先順序,從以償債為主,調整到能持續投資以推動有機成長、在合理時機進行整合式補強(fold-in tuck-in)機會等領域。並且也有機會重新啟動庫藏股回購計畫。當然,一開始會先用於抵銷股權激勵的稀釋,之後再視情況機動進行。
David Roman - Analyst
David Roman - Analyst
Terrific. Thanks so much.
太好了。非常感謝。
Operator
Operator
Matt Miksic, Barclays.
Matt Miksic,巴克萊。
Matthew Miksic - Analyst
Matthew Miksic - Analyst
Thanks so much for taking the question. Congrats on (inaudible) it's busy, busy year. So I wanted to follow up on some of the comments you've made on new product investments and product pipeline. If you could talk a little bit about which business lines those -- which you'd highlight and then maybe timing as to when we might start to see some of the benefits of these investments? And then I have one follow up.
非常感謝讓我提問。恭喜(聽不清),今年真的是非常忙、非常忙的一年。所以我想延伸追問一下你們對新產品投資與產品管線的一些評論。你能否多談一點,這些投資主要落在哪些業務線——你會特別強調哪些——以及我們大概何時可能開始看到這些投資帶來的一些效益?然後我還有一個追問。
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
Sure. So really, let me start with effect is it's really across our portfolio where we actually have really some innovation happening in and certainly, I would start with other (inaudible). Obviously, the Novum pump has been a resounding success as a differentiated product that, again, has got a great customer response. The launch has gone extremely well. Obviously, we got a partial year of that growth last year in 2024. We'll have a full year of that growth heading forward here in 2025. So certainly, Novum is obviously a huge key part of our innovation is, again, really a great success story.
當然。所以其實,我先從整體影響談起:基本上是橫跨我們的產品組合,我們確實在多個領域都有創新在發生;而且我會先從其他(聽不清)開始。(聽不清)。很明顯,Novum 幫浦作為一款具差異化的產品,已經取得了非常顯著的成功,再次證明客戶反應非常好。上市推進得非常順利。顯然,2024 年我們只享受到部分年度的成長貢獻。展望 2025 年,我們將享有完整年度的成長貢獻。因此,Novum 當然是我們創新中的關鍵部分,也是一個非常成功的案例。
Certainly, in Pharma, one of the things that you've heard from us talk about is the -- our need and our opportunity to continue to accelerate with new product launches in Pharma. This past year, we've launched nearly (inaudible), and we anticipate another double-digit year heading into 2025. That is something you should expect from us to continue to do it.
當然,在製藥(Pharma)方面,你們也聽到我們談到的是——我們需要、也有機會持續加速製藥的新產品上市。過去一年,我們推出了將近(聽不清)項產品,而我們預期 2025 年仍會是另一個雙位數的年份。這是你們可以期待我們持續做到的事情。
While there's not necessarily one large molecule that you can tie something to that level of activity is something that we are committed to and we have a great pipeline of opportunities ahead of us. I would tell you that the effect of that, you see the growth that we've had in our pharma business, and so you're seeing the impact of some of that that's already happened, and we anticipate, as we head into next year, we have another solid year from pharma in terms of their innovation as well.
雖然未必有某一個大型分子(large molecule)可以讓你把這些成果直接對應到單一產品,但這種上市活動的強度是我們承諾要維持的,而且我們前方也有很好的機會管線。我會告訴你,這樣的影響,你已經可以從我們製藥業務的成長看得出來,所以你正在看到其中一部分已經發生的成果;而我們也預期,進入明年時,製藥在創新方面也會再交出另一個穩健的年度。
From an HSD perspective --
從 HSD 的角度來看--
Matthew Miksic - Analyst
Matthew Miksic - Analyst
Great. Yeah, that's super helpful. The one other comment I wanted to make is maybe a follow up on Robbie's on HSD, it's just the environment for sort of capital and some of the patient support devices and other things that you're selling (inaudible), beds, that you're selling in hospitals. Just maybe a general comment on that environment, demand cycles, sector trends, anything that can help us gauge where that business is going.
很好。是的,這非常有幫助。我還想補充的一點是,可能延伸 Robbie 對 HSD 的問題:就是你們在醫院銷售的資本設備環境,例如一些病患支援裝置以及其他你們在賣的(聽不清),病床等。能否就那個環境做一些概括性的評論:需求週期、產業趨勢,任何能幫助我們判斷那個業務走向的資訊。
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
Yeah, absolutely. Thanks for the question. Yeah. So I would say, generally speaking, the capital environment is quite good. I think as we talked about this year, our capital orders, particularly in PSS in the US, especially in the second half of the year have actually been very consistent.
好的,當然可以。謝謝你的問題。是的。所以我會說,整體而言,資本支出環境相當不錯。我想如同我們今年談到的,我們的資本訂單,特別是在美國的 PSS,尤其在下半年,其實一直都非常穩定。
And year over year, we had about a 15% growth in those orders, which obviously -- there is a timing element in terms of when the orders turn into cash, that turn the sales. But we certainly had in this next year with some good momentum. We expect to continue to build on that momentum as we have in 2025.
而且年對年來看,這些訂單大約成長了 15%;當然——在訂單何時轉成現金、進而轉成銷售方面,確實存在時間差。但我們帶著不錯的動能進入明年。我們預期在 2025 年會持續在這個動能上再接再厲。
So I would say generally speaking, the capital environment is quite good both from the, I'd say, the monitoring -- the patient monitoring devices as well as from a bed's perspective. Obviously, the continued success with our Progressive Plus model as well. So I think overall, the environment is healthy. We're encouraged by some of the competitive wins that we've had in those areas. As I said, we're anticipating some new products coming out that are better for us as we -- particular to that area we have in 2026.
所以我會說,整體而言,資本環境相當不錯,無論是我所說的監測——病患監測設備,或是從病床的角度來看都是如此。顯然,我們 Progressive Plus 機型也持續成功。因此我認為整體環境是健康的。我們也受到鼓舞,因為我們在這些領域拿下了一些競爭性勝利。如我所說,我們預期會有一些新產品推出,對我們更有利——特別是在該領域,我們在 2026 年會有相關布局。
Brent Shafer - Chair and Interim Chief Executive Officer
Brent Shafer - Chair and Interim Chief Executive Officer
And maybe, Joel, this is Brent just had a comment here. I believe, from what I've seen, there's been a significant improvement in the commercial organization in the US, particularly in those categories. And so I think we're seeing the benefit of upgrades made in that area and real rigor around the commercial processes there. So a credit to those (inaudible).
另外,Joel,我是 Brent,我這邊補充一點。就我所見,美國的商業組織在這些品類上有顯著改善。因此我認為我們正在看到該領域升級所帶來的效益,以及在商業流程上的高度嚴謹。所以要把功勞歸於那些(聽不清)。
Matthew Miksic - Analyst
Matthew Miksic - Analyst
Nice one. Appreciate the color.
很棒。感謝補充說明。
Operator
Operator
Vijay Kumar, Evercore ISI.
Vijay Kumar,Evercore ISI。
Vijay Kumar - Analyst
Vijay Kumar - Analyst
Thank you for taking my question. Joel, maybe my first question was on the margins here. I know the optics, these are apples-to-oranges comparison rate. But the year on year, it does look margins were up 150 basis points. So if you can just break the down rate. What is TSA? How much of this was stranded costs, which were there in fiscal '24 and that's going away? What is the pricing element here with the China have fluid exit, is that a headwind or a tailwind to margins?
謝謝讓我提問。Joel,我第一個問題是關於這裡的利潤率。我知道從表面上看,這是蘋果比橘子的比較。但年對年來看,利潤率似乎上升了 150 個基點。所以你能否把這個拆解一下。TSA 是什麼?其中有多少是擱置成本(stranded costs),也就是在 2024 財年存在、而現在正在消失的部分?另外,這裡的定價因素如何?中國的 have fluid 退出,對利潤率是逆風還是順風?
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
Okay. Yes. Thanks for the question, Vijay. Let me start with the -- I guess, I think the easiest way to bridge our -- what ended the year at our [13.9] to our target that we've talked about and guided to [16.5%]. I think the way to think about that is that if you take the [13.9] and you add about 40 basis points for the 2024 impact of Helene. And then you add about 220 basis points of what would be the stranded cost impact. And then you take about 100 basis points of what we call operational improvements as we head into 2025, those are things like in pricing, particularly in the US in our MPT business.
好的。是的。謝謝你的問題,Vijay。我先從——我想,最容易用來銜接我們年度結束時的 [13.9] 到我們所談到並給出指引的目標[16.5%] 的方式開始說明。我認為可以這樣理解:如果你從 [13.9] 出發,加上約 40 個基點,這是 2024 年 Helene 的影響。然後再加上約 220 個基點,這是我們所謂擱置成本的影響。接著,再加上約 100 個基點,這是我們在邁入 2025 年時所稱的營運改善,包含像是定價,特別是在美國的 MPT 業務。
Those are things like our product mix. One of the things that we talked about is the improvement of our injectables portfolio, the higher growth in our van surgery the improvement in HST, all those are mix elements that add to the -- are positive there.
也包括像是我們的產品組合。我們談到的一點是注射劑(injectables)產品組合的改善、我們在 van surgery 的較高成長、HST 的改善——這些都是組合因素,會對——在那裡帶來正面貢獻。
We talked about some of the leverage from -- that we get from volume growth. And so I think -- and again, obviously, some of the things we talked about new product launches. That's really gets to 100 points of benefit. And obviously, we're reinvesting some of that, but that's a key element of it.
我們也談到一些來自——我們從銷量成長中獲得的營運槓桿。所以我認為——而且再說一次,顯然還有一些我們談到的新產品上市。這些合起來大致就是 100 個基點的效益。當然,我們也會把其中一部分再投資回去,但這是其中一個關鍵要素。
And then there's two elements of the stranded cost and the MSAs that are in the opposite direction. So there's 40 basis points I'll call the net impact of stranded costs that haven't been addressed in 2025 and about a 60 basis point impact of dilution from MSA revenues that are obviously generate a lower margin -- low-single-digit margin from a gross profit perspective.
然後,擱置成本與 MSA 這兩個要素,則是朝相反方向影響。所以有 40 個基點,我會稱之為 2025 年尚未被處理的擱置成本淨影響;另外還有約 60 個基點,來自 MSA 收入的稀釋影響,因為這些收入的利潤率較低——從毛利角度來看是低個位數的利潤率。
So that really is the bridge. And so that takes you from the [13.9] to [16.5]. So hopefully, that gives you some perspective on that. Can you repeat your second question?
所以那確實就是那座橋樑。因此,這會把你從[13.9]帶到[16.5]。希望這能讓你對此有一些視角。你可以重複一下你的第二個問題嗎?
Vijay Kumar - Analyst
Vijay Kumar - Analyst
No, that was extremely helpful, Joel. My second one was on -- if I look at the performance in the quarter, it looks like the beat was -- this was just more than the headwinds from Hurricane Helene coming in slightly better than expectations rate. Can you quantify what the headwind from Helene was in the quarter? And what drove the [big ex] the hurricane impact? It looks like pumps was very strong, so maybe some commentary around pump performance.
不,那非常有幫助,Joel。我的第二個問題是——如果我看本季的表現,看起來超預期——這主要只是因為颶風 Helene 帶來的逆風,比預期稍微好一些。你能量化一下本季 Helene 帶來的逆風有多大嗎?以及是什麼驅動了[big ex]颶風影響?看起來幫浦表現非常強,所以也想聽一些關於幫浦表現的評論。
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
Yeah. Well, I'll start with the quarter then I'll give -- I'll pass it to Heather and talk a little bit about the performance of (inaudible) and pumps in the quarter. So obviously, the headwinds from Helene, the (inaudible) was at 100 basis points in the quarter --
好的。我先從本季談起,然後我會——把問題交給 Heather,請她談一下本季(聽不清)和幫浦的表現。很明顯,Helene 帶來的逆風,(聽不清)在本季約為 100 個基點——
Heather Knight - Executive Vice President, Chief Operating Officer
Heather Knight - Executive Vice President, Chief Operating Officer
Yeah, about $110 million on the top line and $0.10 on the bottom line.
是的,營收端大約 1.10 億美元,獲利端大約 0.10 美元。
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
Yeah. And then -- but obviously, the great news on that is that we actually, we had, we overperformed in terms of the recovery time, in terms of offsetting some of that. So I don't know, maybe Heather, I'll give you -- over to you to talk a little bit about some of that.
是的。然後——但顯然,這裡的好消息是,我們實際上在復原時間上表現優於預期,也在抵銷其中一部分影響方面做得更好。所以我不知道——也許 Heather,我把時間交給你,談談其中一些細節。
Heather Knight - Executive Vice President, Chief Operating Officer
Heather Knight - Executive Vice President, Chief Operating Officer
Sure. So we did better in Q4 with the swift recovery of our North Cove site, thanks to the great work of our team, so about $45 million [better] on IV solutions as a result of the swift recovery that we had out of that location. So did see strength across our infusion therapies business and the infusion pump platform, in particular in the fourth quarter.
當然。我們在第四季表現更好,因為 North Cove 廠區迅速復原,這要歸功於團隊的出色工作;因此,因該地點快速復原,IV solutions(靜脈輸注解決方案)約有 4,500 萬美元的[更好]表現。因此在第四季,我們的輸注治療業務以及輸注幫浦平台整體都呈現強勁表現,尤其是後者。
So I'll say we're very happy with the launch of Novum IQ and where we are. The teams are doing a great job driving this new platform. If you recall, Baxter placed a pretty big bet to internally develop a brand new to market and novel infusion pump platform, both with the hardware, software, and digital platform, and we're seeing it pay off.
我想說,我們對 Novum IQ 的上市以及目前的進展非常滿意。團隊在推動這個新平台方面做得非常出色。如果你還記得,Baxter 曾下了相當大的賭注,選擇內部自行開發一個全新、具創新性的輸注幫浦平台,涵蓋硬體、軟體與數位平台,而我們正看到這項投入開始回收成果。
So our infusion business grew 50% last year in 2024, and we're expecting another great year this year in 2025. And it's not only important because we get the revenue from the hardware and software, but also because we get to pull through very consistent revenue over the life of that pump. So share capture, competitive gains are really important. And customer satisfaction right now is very high both on the implementation of the pump as well as the EMR integration with the new platform.
我們的輸注業務在 2024 年去年成長了 50%,而我們預期 2025 年今年也會是非常好的一年。這不僅重要在於我們能從硬體與軟體取得營收,也因為在幫浦的整個使用壽命期間,我們還能帶動非常穩定、持續的後續營收。因此,市占擴張、競爭性勝出非常重要。而目前客戶滿意度非常高,無論是幫浦導入實施,或是新平台與 EMR 的整合。
And this was developed in collaboration with our customers. So again, we're starting to see -- the benefit of that, we took multiple points of market share last year in 2024, and we're expecting to see more of the same, more competitive gains in 2025.
而這是與我們的客戶共同合作開發的。所以我們再次開始看到——這樣做的效益:我們在 2024 年去年拿下了好幾個百分點的市占,而我們預期 2025 年也會看到類似情況,取得更多競爭性勝出。
And then we have some new complementary digital suites that are now launching that will be a great complement to this launch midyear in 2024 that we released. So I'll tell you, I'm pretty excited about where we are in this new chapter, the new pace momentum that we're building around the Novum platform and IVs are stable. We've gone through the GPO reside and are in line with our expectations, if not slightly better than we expected.
另外,我們也有一些新的互補性數位套件正在推出,將會很好地補強我們在 2024 年年中發布的這次上市。所以我想說,我對我們在這個新篇章的位置、以及我們圍繞 Novum 平台所建立的新節奏與動能感到相當振奮,而 IV 也維持穩定。我們已經走過 GPO 重新簽約(reside),結果符合我們的預期,甚至略優於預期。
So we're expecting a great rebound in 2025 and certainly really appreciate our customer support during the recovery of hurricane Helene and hats off to the Baxter team for the fast recovery. So thanks for the question today.
因此,我們預期 2025 年會有很好的反彈;同時也非常感謝客戶在 Helene 颶風復原期間的支持,也要向 Baxter 團隊的快速復原致敬。所以謝謝你今天的提問。
Vijay Kumar - Analyst
Vijay Kumar - Analyst
That's helpful. Thank you.
很有幫助。謝謝。
Brent Shafer - Chair and Interim Chief Executive Officer
Brent Shafer - Chair and Interim Chief Executive Officer
Yeah, this is Brent. Just to add on -- yeah, I'd just like to recognize Heather and her team and really all the folks who worked on North Cove recovery, it's hard to explain it in a financial setting, but the work to deal with the disaster situation to work through that effectively bring the plant back up and really look after the community at the same time, it's just world-class response by the folks who are involved. And that's -- personally want to thank them all, especially Heather.
是的,我是 Brent。補充一下——是的,我也想表揚 Heather 和她的團隊,以及所有參與 North Cove 復原工作的同仁;在財務場合很難把它說清楚,但在災害情境下所做的工作、有效地處理並讓工廠恢復運作,同時也照顧社區,這真的是世界級的應對表現,來自所有參與其中的人。而我——個人想感謝大家,尤其是 Heather。
Vijay Kumar - Analyst
Vijay Kumar - Analyst
Thank you. Very helpful answers.
謝謝。答案非常有幫助。
Operator
Operator
Travis Steed, Bank of America Securities.
Travis Steed,美國銀行證券(Bank of America Securities)。
Travis Steed - Analyst
Travis Steed - Analyst
I'll follow up a question on the tailing side. And obviously, a great job on the fast recovery, I think it went better than most expected. But I was just thinking about how you think about the book of [sailing] business kind of before and after the hurricane you see customers add a second source and how you're kind of thinking about the share of that? And then I have a follow-up question on free cash flow.
我想追問一個關於尾端(tailing)方面的問題。而且很明顯,你們在快速復原上做得非常好,我認為結果比大多數人預期的更好。但我在想,你們如何看待颶風前後這本[sailing]業務的訂單/業務量(book)——你們是否看到客戶增加第二來源,以及你們如何看待市占的變化?然後我還有一個關於自由現金流的追問。
Heather Knight - Executive Vice President, Chief Operating Officer
Heather Knight - Executive Vice President, Chief Operating Officer
Yeah. Thanks for the question, Travis. So as I mentioned to Vijay, I mean, our expectations are in line or even slightly better. I think because of the fast recovery that we had, quite honestly, out of North Cove. So we're not seeing as many customers take on a second source, particularly because as we've mentioned, we're back to pre-hurricane levels at this point.
好的。謝謝你的問題,Travis。如同我先前對 Vijay 提到的,我們的預期符合、甚至略優於原先預期。我想這相當程度上是因為我們在 North Cove 的復原速度很快,坦白說。因此我們沒有看到那麼多客戶採用第二來源,尤其是因為如我們所提到的,目前我們已回到颶風前的水準。
So these new US GPO contracts, in particular, started on January 1 and February 1. So now that we've fully recovered most customers are still committed to their remaining compliance and minimum committed volumes that they've given to Baxter. So we're pleased with the response on our customers sticking with Baxter.
這些新的美國 GPO 合約,特別是從 1 月 1 日與 2 月 1 日開始生效。因此,現在我們已完全復原,多數客戶仍然承諾遵守其剩餘的合規要求,以及他們對 Baxter 所承諾的最低採購量。所以我們對客戶持續支持 Baxter 的反應感到滿意。
During this time, we know the fourth quarter wasn't easy for them, but we proved to them the resiliency that we have in the investments, quite honestly, that we've made over the last few years and our global network and activating that during Helene certainly helped and relieve some of the pressure. So we think that that's pretty unique to Baxter and the hundreds of millions that we've invested in our platform and IV solutions due to the critical nature that they play in healthcare.
在這段期間,我們知道第四季對他們並不容易,但我們向他們證明了我們的韌性——坦白說,這來自於我們過去幾年所做的投資、我們的全球網路,以及在 Helene 期間啟動該網路,確實有助於緩解部分壓力。因此我們認為,這對 Baxter 而言相當獨特;我們在平台與 IV solutions 上投入了數億美元,因為它們在醫療照護中扮演關鍵角色。
So again, in line or slightly better and working closely with our customers to make sure that they can resume normal clinical practice as they've had, and patients can get the critical solutions that they need.
所以再次強調,表現符合或略優於預期;我們也與客戶密切合作,確保他們能恢復正常的臨床作業,並讓病患能取得他們所需的關鍵解決方案。
Travis Steed - Analyst
Travis Steed - Analyst
Great. That's helpful. And then I did want to ask on free cash flow generation. I know there was a lot of adjustments this quarter. How should we think about some of these adjustments going forward? When do you think you can kind of get back to kind of 80% free cash flow conversion? I don't think you gave a guidance for free cash flow next year. But curious how you're thinking about that. And then the Front Line Care write-down. Any more color on that on other if that's kind of a change in the growth expectations for that business long term?
很好。這很有幫助。接著我想問自由現金流的產生。我知道本季有很多調整項。我們應該如何看待這些調整項在未來的走向?你們認為何時能回到大約 80% 的自由現金流轉換率?我想你們沒有提供明年的自由現金流指引。但想了解你們的思考方向。另外,Front Line Care 的減記。能否再多提供一些背景?這是否代表對該業務長期成長預期有所改變?
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
Yeah. Thanks, Travis. So free cash flow, the way I would think about that is that we have talked about the fact that we want to have an 80% conversion of net earnings free cash flow and I expect that to be, generally speaking, what we'll do in the course of the year with caveat to that. And that is in the first quarter, we're anticipating some negative impacts from -- think about it this way, it's two things from a working capital perspective.
是的。謝謝你,Travis。所以自由現金流,我的看法是:我們一直談到希望淨利轉換為自由現金流的比率達到80%,而我預期一般而言,我們在一年當中會做到這點,但也有一些但書。也就是在第一季,我們預期會有一些負面影響——從營運資金的角度來看,可以這樣理解,主要有兩件事。
Number one is some of the expenses we incurred in Q4 related to Hurricane Helene are actually to be paid into one. And then secondly, there is going to be some level of restock from an inventory perspective, that could have a negative drag on cash. So I would think about that number for this year is somewhere more like [below 70s] -- but that is mostly impacted by the first quarter, and I anticipate a much more normal cash conversion in the third quarter of the year. And obviously, going forward, we'll hopefully continue to improve that as we go forward.
第一,是我們在第四季因颶風Helene所產生的一些費用,實際上會在第一季支付。第二,從庫存角度來看,將會有一定程度的補庫存,這可能會對現金造成負面拖累。因此我會認為今年這個數字大概會更接近[低於70%區間]——但這主要是受到第一季的影響,而我預期在今年第三季會回到更正常的現金轉換水準。當然,往後我們也希望能持續改善。
Regarding the write-down Front Line Care, the other way I would look at that, Travis, is we do a lot to year review of the -- our goodwill and other (inaudible) as it relates to those assets. And 2024 was obviously an impactful here from an FLC perspective. So I guess I'd characterize it more as impact to 2024 on the model that with any type of overarching concern about the growth prospects going forward.
關於Front Line Care的減記,Travis,我會用另一種方式來看:我們每年都會對——我們的商譽以及其他(聽不清)就這些資產進行年度檢視。而2024年從FLC的角度來看顯然是影響很大的一年。所以我想我會把它更描述為:對2024年模型的影響,而不是對未來成長前景有任何整體性的疑慮。
Travis Steed - Analyst
Travis Steed - Analyst
Great. Thank you.
很好。謝謝。
Operator
Operator
Lawrence Biegelsen, Wells Fargo.
Lawrence Biegelsen,富國銀行。
Lawrence Biegelsen - Analyst
Lawrence Biegelsen - Analyst
Thanks for taking the questions. Congrats on a nice finish to the year here. Brent, I was hoping to ask you two questions. First, David earlier in the call, talked about the challenges Baxter has had in recent years. How do you think about the pros and cons of an external versus internal candidate for CEO, bringing in a fresh perspective versus someone who kind of already knows Baxter. I have one follow up for you.
謝謝讓我提問。恭喜今年收官表現不錯。Brent,我想問你兩個問題。首先,David在稍早的電話會議中談到Baxter近年面臨的挑戰。你如何看待從外部與內部選擇CEO候選人的利弊:引進新視角 versus 找一位已經相當了解Baxter的人。我還有一個追問。
Brent Shafer - Chair and Interim Chief Executive Officer
Brent Shafer - Chair and Interim Chief Executive Officer
Well, I mean that's the big question, I guess. And the Board is very focused on that because there are pros and cons to either solution. Obviously, an internal candidate knows all the details of the business, how it runs, how it operates, an external one can bring a fresh perspective, but they have to ramp up quickly to try to catch that same level of knowledge, which takes a while, especially in a complex business.
嗯,我想這就是關鍵問題。董事會非常專注在這件事上,因為兩種方案各有利弊。顯然,內部候選人了解業務的所有細節、運作方式與營運模式;外部候選人可以帶來新視角,但他們必須快速上手,才能追上同等程度的知識,而這需要時間,尤其是在複雜的業務中。
So I can just tell you that it is a full Board activity. The Board is very focused on this. And though they would like to move as quickly as possible the general sense is it's more important to get the right fit for the company at this point in time than it is to necessarily be quick. So I hope that gives you a little flavor for it.
所以我只能告訴你,這是全體董事會共同參與的事項。董事會非常重視這件事。雖然他們希望盡可能快地推進,但整體共識是:在此時此刻,找到最適合公司的人選比單純追求速度更重要。希望這能讓你稍微了解一些。
Lawrence Biegelsen - Analyst
Lawrence Biegelsen - Analyst
That does. Thank you. And secondly, Brent, how did you evaluate the guidance as interim CEO? And how do you think about the process for the permanent CEO to reevaluate it. You know that just to be candid, right, you know the investors typically think a new CEO will come in and want to put his or her stamp on the guidance, maybe want to change investment priorities and things like that. So how did you think about that?
有的。謝謝。第二個問題,Brent,你以臨時CEO的身分是如何評估這份指引的?你又如何看待未來正式CEO重新評估指引的流程?坦白說,投資人通常會認為新CEO上任後會想在指引上打上自己的烙印,可能會調整投資優先順序之類的。所以你是怎麼思考這件事的?
Brent Shafer - Chair and Interim Chief Executive Officer
Brent Shafer - Chair and Interim Chief Executive Officer
How do I think it coming in as an interim you mean?
你的意思是我以臨時身分上任時怎麼看嗎?
Lawrence Biegelsen - Analyst
Lawrence Biegelsen - Analyst
Well, yeah, I mean is there a risk the new CEO comes in and says: hey, we need to invest more. And changes the guidance.
對,是的。我的意思是,新CEO上任後是否存在這樣的風險:他或她說「我們需要加大投資」,然後改變指引。
Brent Shafer - Chair and Interim Chief Executive Officer
Brent Shafer - Chair and Interim Chief Executive Officer
Yeah. Well, I think we've seen at a Board level seeing the three-year look at the business and are aware of the details and what and the drivers and being on Board now and in the business feel good. I feel like there's solid plans in place. Of course, when you have another person at the helm, and I'm an interim leader. So my focus is really on executing the plans that are in place. Another person may put a different filter on it, but the general situation around our markets and our offerings are known very well in the business.
是。我認為在董事會層面,我們已經看過對業務的三年展望,也了解細節、內容與驅動因素;而我現在在董事會、也在業務中,感覺良好。我覺得已有扎實的計畫在執行。當然,當你換了掌舵者,而我又是臨時領導人。所以我的重點是把既定計畫執行到位。換個人可能會用不同的視角來看,但我們的市場與產品組合的整體情況,在公司內部是非常清楚的。
So anything -- anyone coming in would be building on that. I guess that's -- I can assume. It's kind of a hard question to answer because it depends.
所以任何——任何新進來的人都會在此基礎上延伸。我想——我可以這麼假設。這題有點難回答,因為要看情況。
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
I think the one thing I would just give out the opportunity that he's talked about it. I would just reiterate the fact that this is a great opportunity for someone to come in. And again, Brent has a perspective on that, and maybe you could share that as well. But I think as we talked about some of the key strategic initiatives that I've done over these last three years, again, there's really the last couple of years, there's a really nice opportunity for some of it coming here and take a company that really -- I think it has actually set up all for success. And so I don't know (multiple speakers) --
我想我唯一想補充的是,既然他提到了這個機會。我想再次強調:這對某位新加入的人來說是一個很好的機會。而且,Brent對此也有看法,也許你也可以分享一下。但我認為,正如我們談到我在過去三年、尤其是最近幾年所推動的一些關鍵策略舉措,確實為某位新加入的人提供了很好的機會,來接手一家公司——我認為其實已經為成功做好了各方面的準備。所以我不知道(多位講者) --
Brent Shafer - Chair and Interim Chief Executive Officer
Brent Shafer - Chair and Interim Chief Executive Officer
Yeah, my comment a little bit about that. I mean the organization, as you know, has been consumed with a lot of projects. We're a very tough detailed work -- working through these separations. And there is a real energy in the organization to turn now to growth and innovation. And so you can feel it.
是的,我稍微補充一下。如你所知,組織一直被許多專案所占據。我們在這些分拆作業中做了非常艱鉅、細節繁重的工作——一路把它們處理完。而現在組織內部有一股真正的能量,準備把重心轉向成長與創新。你能感受到。
You really can. And that is a real opportunity here. There are good leaders ready to move it forward. And I think whoever comes into the role, that is the key piece to drive us that profitable growth from the base that's been down now because a lot of clean up has been done.
真的能。而這裡確實是一個很大的機會。有很好的領導團隊已準備好推動公司向前。我認為不論誰接任這個角色,關鍵都在於:在我們目前的基礎上——因為很多清理工作已經完成、基期也已經下來——去推動我們實現那種具獲利性的成長。
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
All right. Very helpful. Thank you for taking the questions.
好的。非常有幫助。謝謝讓我提問。
Operator
Operator
Danielle Antalffy, UBS.
Danielle Antalffy,瑞銀。
Danielle Antalffy - Analyst
Danielle Antalffy - Analyst
Thank you so much for taking the question. And Heather, excited to work with you. Just a quick question. Actually, Larry's question is a good segue into Brent and Joel and Heather. Just as we look to 2025 and sort of some of the pipeline drivers specific to 2025 and maybe even 2026, I know you guys talked about like 10 product launches in Pharma, for example. But any color you can give on sizing these and what we, as analysts and investors, can look forward to over the next 12 to 24 months. And that's all.
非常感謝讓我提問。Heather,很期待與你合作。我只有一個簡短問題。其實Larry的問題正好銜接到Brent、Joel和Heather。當我們展望2025年,以及一些特別針對2025年、甚至2026年的產品線/研發管線驅動因素時,我知道你們提到例如在Pharma會有大約10個產品上市。但你們能否提供一些補充資訊,讓我們了解這些產品的規模量級,以及未來12到24個月內,我們作為分析師與投資人可以期待什麼。就這樣,謝謝。
Joel Grade - Executive Vice President, Chief Financial Officer
Joel Grade - Executive Vice President, Chief Financial Officer
Sure. I'll start, and others can chime in as they like. So I guess what I'll start with what I'd call a few of the kind of key drivers as we think about our guidance in 2025 a year ahead of us. See, number one, we continue to have strong growth in MPT. I think obviously, as we mentioned a little earlier, the full year of the Novum launches to get -- we're really excited about that.
好的。我先開始,其他人也可以視情況補充。我想我會先從幾個我們在展望2025年(距今一年)指引時所考量的關鍵驅動因素談起。第一,我們在MPT持續維持強勁成長。我想很明顯地,如同我們稍早提到的,Novum新品上市帶來的全年貢獻——我們對此非常興奮。
Our (inaudible) surgery, we're anticipating continued mid-single-digit growth there. Our Clinical Nutrition business, which actually kind of an interesting notice, has started just to penetration into the [ASC] space. So we've seen some nice growth there and anticipate that continuing by the end of next year as well as the impact of GPO pricing. That's a strong element in that business.
我們的(聽不清)外科業務,我們預期仍將維持中個位數成長。我們的臨床營養業務其實有個有趣的現象,已開始逐步滲透到[ASC]場域。因此我們看到不錯的成長,並預期到明年年底仍會延續,同時也會反映GPO定價的影響。這是該業務的一個強勁要素。
We talked a little earlier about the recovery of HFC and the continued momentum on the capital side in particular, PFS of the US as well as the stabilization of FLC. We talked about Pharma is sort of the key of the innovations of new product launches and the mix improvement there of injectables relative to compounding, I'd say, even stabilization on the anesthesia side. I think the -- so I think that's really at the top line.
我們稍早也談到HFC的復甦,以及資本端(尤其是美國的PFS)持續的動能,並且FLC趨於穩定。我們也談到製藥業務,關鍵在於新產品上市的創新,以及注射劑相對於配製(compounding)的組合改善;我會說麻醉端也趨於穩定。我認為——所以我認為這些主要反映在營收端。
And then the drivers of (inaudible) that I talked about the area, some of the GPO pricing, the new product launches the mix continued improvements (inaudible), our supply chain with our margin improvement programs and value leverage.
接著是我提到的(聽不清)方面的驅動因素,包括部分GPO定價、新產品上市、組合持續改善(聽不清),以及我們供應鏈端透過毛利改善計畫與價值槓桿所帶來的效益。
And then over the course of the year, continued impact from driving out some of the training costs, that we've talked about here. So I think those are really the things to look forward to. There are few product launch with respect to just in general again, a renewed focus on that an accelerated focus there that show some impact in the ways that I talked about the '25 but also sets up for some impact beyond that. (multiple speakers)
此外,在一年當中,持續把我們在此談到的一些訓練成本逐步移除,也會帶來持續影響。所以我認為這些就是值得期待的重點。另外,整體而言也會有幾項產品上市——再次強調,我們會重新聚焦並加速推進,這不僅會以我談到的方式在2025年帶來一些影響,也會為之後帶來更多效益奠定基礎。(多位發言者)
Heather Knight - Executive Vice President, Chief Operating Officer
Heather Knight - Executive Vice President, Chief Operating Officer
I'll chime in. Yeah, I'm looking forward to working with you, too. This is Heather. So some things that I'm excited about, I mean, the pump platform, as I mentioned, is something that we will continue to build on, and we have additional launches to support Novum IQ and a gateway now that can work across our entire portfolio. So really excited about that in a connected ecosystem in the hospital, which is going to help clinical decision support and more personalized patient care.
我補充一下。是的,我也很期待與你合作。我是Heather。有幾件我很期待的事:如我提到的,幫浦平台是我們會持續深化的方向;我們也會有更多上市計畫來支援Novum IQ,以及一個現在可橫跨我們整個產品組合運作的閘道(gateway)。所以我們對此非常興奮——在醫院端打造互聯的生態系,這將有助於臨床決策支援與更個人化的病患照護。
I mean that's something that was the original thesis of the Hill-Rom acquisition, and we're starting to really see good pilots and momentum with our customers on that. HST is going to be introducing some new products. They got launches coming out throughout 2025 and early '26. We're still seeing great momentum on Progressive Plus and PSF, so that continues to pay good dividends and taking market share there.
這其實是當初收購Hill-Rom的核心論點之一,而我們開始真正看到與客戶合作的良好試點與動能。HST也將推出一些新產品。他們在2025年及2026年初會陸續有新品上市。我們在Progressive Plus與PSF上仍看到很強的動能,因此持續帶來良好回報,並在那裡取得市占。
And then Pharma is hitting a really exciting cadence of new product launches getting into more complex molecules, 10 to 12 launches a year that are really going to help buoy and as Joel mentioned, the margins of that business. They're really focused on that. And when they hit this innovation cycle that they're on right now. So those are some of the things that I'm personally excited about. And then he mentioned alternate site.
另外,製藥業務正進入非常令人振奮的新產品上市節奏,開始切入更複雜的分子,每年約10到12個上市案,將真正有助於支撐該業務;如Joel所提,也會改善該業務的毛利。他們非常聚焦在這點。而且他們正處於目前這個創新循環之中。以上是我個人特別期待的一些事情。另外他也提到替代照護場域(alternate site)。
We made investments two years ago an alternate site in the United States. And we are starting to see dividends paid there in the nutrition portfolio and some small tuck-in licensing and distribution deals that we did in MPT, and those are starting to bear fruit. So that momentum in the US will continue. So those are just a few things that I'm personally excited about.
兩年前我們在美國的替代照護場域做了投資。我們開始看到這些投資帶來回報,反映在營養產品組合上,以及我們在MPT做的一些小型補強式(tuck-in)的授權與經銷交易,這些都開始開花結果。因此,美國的這股動能將會延續。以上只是我個人特別期待的幾點。
So when I talked about a new rhythm, a new pace, and momentum that we're building, we're definitely starting to see that across the portfolio and those investments that we made bearing fruit now moving into '25 and '26.
所以當我談到新的節奏、新的步調,以及我們正在建立的動能時,我們確實開始在整個產品組合看到這些投資的成果,並將延續到2025年與2026年。
Brent Shafer - Chair and Interim Chief Executive Officer
Brent Shafer - Chair and Interim Chief Executive Officer
Yeah. Thanks, Heather. This is Brent. I'd just add to that, I sort of referred to it, but really starting right now, we're putting the emphasis on accelerating time to market, innovation development. So that is an area, a very strong focus right now is how to speed up that whole innovation cycle and get product solutions to market faster. So that will be ongoing work.
是的。謝謝你,Heather。我是Brent。我再補充一下,我先前也提到過,但其實從現在開始,我們會把重點放在加速上市時程與創新開發。因此目前一個非常重要的聚焦領域,就是如何加快整個創新循環,讓產品解決方案更快推向市場。所以這會是持續進行的工作。
Danielle Antalffy - Analyst
Danielle Antalffy - Analyst
Thank you.
謝謝。
Operator
Operator
Ladies and gentlemen, those are all the questions that time allows us to take. Therefore, that concludes today's question-and-answer session and today's conference call. We thank you for your participation. You may now disconnect.
各位女士、先生,受限於時間,我們能回答的問題到此為止。因此,今天的問答環節以及今天的電話會議到此結束。感謝各位的參與。您現在可以掛線。